No Data
No Data
Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)
10-K: FY2024 Annual Report
12 Health Care Stocks Moving In Tuesday's Intraday Session
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Express News | D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $8
Express News | Reviva Pharmaceuticals: Expects to Report Material Weaknesses in Internal Control Over Financial Reporting